TrialsgrambetaRCTs are beautiful
ESC Congress 2026Apresentado sáb., 29 de ago. · 08:30 GMT+2Hot Line 2Todos os ensaios Hot Line →

AMUNDSEN

2026

Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world

In 2,161 patients with acute myocardial infarction undergoing PCI, evolocumab started before PCI increased achievement of an LDL-C reduction of ≥50 % to below 1.4 mmol/L at 12 months compared with standard lipid-lowering care.

Resultado

Eficácia: Achievement of both a ≥50% LDL-C reduction from baseline and LDL-C <1.4 mmol/L (55 mg/dL) at 12 months; main clinical endpoint the composite of all-cause death or unplanned cardiovascular hospitalisation at 12 monthsadjusted OR 5,54 (IC 95% 4,50-6,82) · P < 0,001

Abaixo de 1 a favor de standard lipid-lowering care, acima de 1 a favor de evolocumab started before PCI.

Taxas de eventos
Diferença absoluta
42,0 pontos
NNT
3

A diferença absoluta e o NNT derivam das taxas de eventos.

Também relatado: Primary lipid endpoint met: median LDL-C at 6 weeks 16 vs 56 mg/dL. No clinical benefit: death or unplanned cardiovascular hospitalisation at 12 months 159/1087 (14.6%) vs 165/1074 (15.4%), adjusted OR 0.94 (95% CI 0.73–1.19), p=0.59

Publicação original
Subtema
PCSK9 inhibition in ACS
Desenho
International, investigator-initiated Phase IV PROBE RCT, 1:1, first evolocumab dose given before PCI, 12-month primary follow-up (clinical follow-up continuing to 2028)
Relevância
Importante: um de vários pilares.
Fonte
Montalescot G, Ferrari E, Souteyrand G, et al. JAMA. 2026; published online 29 August.doi 10.1001/jama.2026.17302

Discussão e crítica

Giving the PCSK9 antibody before the wire crosses does what the pharmacology promises: four in five reach the guideline target at a year against two in five, with a median LDL-C of 16 mg/dL at six weeks. What it does not do, over twelve months, is change death or cardiovascular readmission: an open-label trial powered for a laboratory endpoint, not for events. The lipid result is the argument for starting early; the clinical arm is the reminder that a year is short for a curve that separates late.

Discutido em podcasts